Kringle Pharma, Inc.
Records under this name other than the patents Kringle Pharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Showing 1 to 10 of 10 · Back to Kringle Pharma, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,518,880 | Therapeutic Agent for Spinal Cord Injuries Formerly held In force · High confidence | In force | High confidence | |
| US 8,575,099 | Agent for Treating Polyglutamine Aggregation-Caused Disease or Suppressing Onset Thereof Lapsed on the fee record Ended Nov 5, 2025 · High confidence | Lapsed on the fee record | Ended Nov 5, 2025 | High confidence |
| US 8,003,607 | HGF Precursor Protein Variant and Active Protein Thereof Lapsed on the fee record Ended Aug 23, 2023 · High confidence | Lapsed on the fee record | Ended Aug 23, 2023 | High confidence |
| US 7,563,768 | Asthma preparation Lapsed on the fee record Ended Jul 21, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jul 21, 2021 | From the USPTO record |
| US 8,383,588 | Fibrosis inhibitor for implanted organ Lapsed on the fee record Ended Feb 26, 2021 · From the USPTO record | Lapsed on the fee record | Ended Feb 26, 2021 | From the USPTO record |
| US 8,278,270 | HGF precursor protein variant and active protein thereof Lapsed on the fee record Ended Oct 2, 2020 · From the USPTO record | Lapsed on the fee record | Ended Oct 2, 2020 | From the USPTO record |
| US 8,076,289 | Fibrosis inhibitor for implanted organ Lapsed on the fee record Ended Dec 13, 2019 · From the USPTO record | Lapsed on the fee record | Ended Dec 13, 2019 | From the USPTO record |
| US 7,838,494 | Differentiation- or regeneration-inducing agent for alveoli Lapsed on the fee record Ended Nov 23, 2018 · From the USPTO record | Lapsed on the fee record | Ended Nov 23, 2018 | From the USPTO record |
| US 7,807,177 | Segment of glycosylation-deficient HGFalpha-chain Lapsed on the fee record Ended Oct 5, 2018 · From the USPTO record | Lapsed on the fee record | Ended Oct 5, 2018 | From the USPTO record |
| US 7,696,170 | Fibrosis inhibitor for implanted organ Lapsed on the fee record Ended Apr 13, 2014 · From the USPTO record | Lapsed on the fee record | Ended Apr 13, 2014 | From the USPTO record |